Douglas Miehm Analyst Performance

Analyst at Royal Bank Of Canada

Douglas Miehm is a stock analyst at Royal Bank Of Canada focused in the medical sector, covering 11 publicly traded companies. Over the past year, Douglas Miehm has issued 11 stock ratings, including buy and hold recommendations. While full access to Douglas Miehm's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Douglas Miehm's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 84 Last 10 Years
Buy Recommendations: 51.81% 43 Buy Ratings
Companies Covered: 11 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	51.8%	43 ratings
Hold	48.2%	40 ratings
Sell	0.0%	0 ratings

Out of 83 total stock ratings issued by Douglas Miehm at Royal Bank Of Canada, the majority (51.8%) have been Buy recommendations, followed by 48.2% Hold.

Best & Worst Calls

Best Call
000.0%
AUPH
Dec 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
BHC
Jul 2015
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	63.6% of companies on NASDAQ	7 companies
NYSE	18.2% of companies on NYSE	2 companies
TSE	9.1% of companies on TSE	1 company
OTCMKTS	9.1% of companies on OTCMKTS	1 company

Douglas Miehm, an analyst at Royal Bank Of Canada, currently covers 11 companies listed on NASDAQ, NYSE, TSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 10 companies	90.9%
	Miscellaneous 1 company	9.1%

Douglas Miehm of Royal Bank Of Canada specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 3 companies	27.3%
PHARMACEUTICAL PREPARATIONS 3 companies	27.3%
MED - DRUGS 1 company	9.1%
MED - GENERIC DRG 1 company	9.1%
MEDICAL SERVICES 1 company	9.1%
MEDICAL INSTRUMENTS & SUPPLIES 1 company	9.1%
Miscellaneous 1 company	9.1%

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MNKD MannKind	8/26/2025	Boost Price Target	$3.95	$8.00	Outperform
LGND Ligand Pharmaceuticals	8/8/2025	Boost Price Target	$150.84	$185.00	Outperform
MNKD MannKind	8/7/2025	Lower Price Target	$3.42	$7.00	Outperform
AUPH Aurinia Pharmaceuticals	8/1/2025	Boost Price Target	$10.01	$9.00	Outperform
MNKD MannKind	7/23/2025	Lower Price Target	$3.93	$8.00	Outperform
BHC Bausch Health Cos	5/2/2025	Boost Price Target	$5.45	$10.00	Sector Perform
BLCO Bausch + Lomb	4/4/2025	Lower Price Target	$12.32	$17.00	Outperform
ONCY Oncolytics Biotech	3/10/2025	Lower Price Target	$0.66	$5.00	Outperform
BLCO Bausch + Lomb	2/20/2025	Lower Price Target	$16.11	$18.00	Outperform
BHC Bausch Health Cos	1/30/2025	Lower Price Target	$7.41	$10.00	Sector Perform
BLCO Bausch + Lomb	1/29/2025	Lower Price Target	$17.79	$22.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.